PE20221036A1 - Profarmacos antivirales y formulaciones de los mismos - Google Patents

Profarmacos antivirales y formulaciones de los mismos

Info

Publication number
PE20221036A1
PE20221036A1 PE2022000382A PE2022000382A PE20221036A1 PE 20221036 A1 PE20221036 A1 PE 20221036A1 PE 2022000382 A PE2022000382 A PE 2022000382A PE 2022000382 A PE2022000382 A PE 2022000382A PE 20221036 A1 PE20221036 A1 PE 20221036A1
Authority
PE
Peru
Prior art keywords
fluoro
ethynyl
amino
methyl
prodrugs
Prior art date
Application number
PE2022000382A
Other languages
English (en)
Spanish (es)
Inventor
Arnab Kumar Chatterjee
Anil Kumar Gupta
Anders Mikal Eliasen
Sean Barry Joseph
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of PE20221036A1 publication Critical patent/PE20221036A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PE2022000382A 2019-09-11 2020-09-11 Profarmacos antivirales y formulaciones de los mismos PE20221036A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962898679P 2019-09-11 2019-09-11
PCT/US2020/050519 WO2021050961A1 (en) 2019-09-11 2020-09-11 Antiviral prodrugs and formulations thereof

Publications (1)

Publication Number Publication Date
PE20221036A1 true PE20221036A1 (es) 2022-06-17

Family

ID=74866690

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2022000382A PE20221036A1 (es) 2019-09-11 2020-09-11 Profarmacos antivirales y formulaciones de los mismos
PE2022000389A PE20221037A1 (es) 2019-09-11 2020-09-11 Profarmacos antivirales y composiciones farmaceuticas de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2022000389A PE20221037A1 (es) 2019-09-11 2020-09-11 Profarmacos antivirales y composiciones farmaceuticas de los mismos

Country Status (18)

Country Link
US (3) US20220323476A1 (enExample)
EP (2) EP4028019A4 (enExample)
JP (4) JP7703518B2 (enExample)
KR (2) KR20220066303A (enExample)
CN (4) CN114929236B (enExample)
AU (2) AU2020346908B2 (enExample)
BR (2) BR112022004424A2 (enExample)
CA (2) CA3150418A1 (enExample)
CL (4) CL2022000601A1 (enExample)
CO (2) CO2022005128A2 (enExample)
CR (2) CR20220110A (enExample)
DO (2) DOP2022000056A (enExample)
IL (4) IL290861B2 (enExample)
MX (4) MX2022002897A (enExample)
PE (2) PE20221036A1 (enExample)
PH (2) PH12022550528A1 (enExample)
UA (1) UA130229C2 (enExample)
WO (2) WO2021050961A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
CA3146679A1 (en) * 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
KR20220066303A (ko) * 2019-09-11 2022-05-24 더 스크립스 리서치 인스티튜트 항바이러스 전구약물 및 이의 약제학적 조성물
JP7703538B2 (ja) * 2019-12-09 2025-07-07 ヴィーブ、ヘルスケア、カンパニー カボテグラビルを含んでなる医薬組成物
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
WO2021188959A1 (en) * 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
EP4281083A4 (en) 2021-01-25 2025-01-01 Brii Biosciences, Inc. COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS
EP4281081A4 (en) 2021-01-25 2025-05-14 Brii Biosciences, Inc. ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF
MX2023010797A (es) * 2021-03-16 2023-09-27 Scripps Research Inst Profarmacos antivirales de entecavir (etv) y formulaciones de los mismos.
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN121358747A (zh) 2023-06-27 2026-01-16 吉利德科学公司 核苷逆转录酶易位抑制剂的固体形式
CN121419986A (zh) * 2023-06-27 2026-01-27 吉利德科学公司 用于制备抗病毒前药的方法和中间体
FI20245041A1 (en) 2024-01-17 2025-07-18 Metso Finland Oy Precipitation of calcium compounds in liquid extraction systems

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283067A (en) 1987-01-30 1994-02-01 Ciba-Geigy Corporation Parenteral suspensions
US5192749A (en) 1990-05-21 1993-03-09 Syntex (U.S.A.) Inc. 4'-substituted nucleosides
FR2694693B1 (fr) * 1992-07-28 1994-10-28 Abrax Bio Labs Sa Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
ATE250622T1 (de) 1999-05-12 2003-10-15 Yamasa Corp 4'-c-ethynyl-pyrimidine nukleoside
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
EA200800932A1 (ru) 2005-09-26 2008-10-30 Фармассет, Инк. Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090274686A1 (en) 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
WO2013090420A2 (en) 2011-12-12 2013-06-20 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
MX391226B (es) 2015-09-23 2025-03-21 Merck Sharp & Dohme Llc Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
US10745428B2 (en) * 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
FR3053281B1 (fr) 2016-06-30 2020-03-27 Banque De France Procede de fabrication d'un document de securite presentant un signe de securite a contraste de brillance
US10185393B2 (en) 2017-04-03 2019-01-22 Facebook Technologies, Llc Waveguide display with spatially switchable grating
PT3706762T (pt) * 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
US20190185508A1 (en) 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
EP3762396A1 (en) 2018-03-07 2021-01-13 GlaxoSmithKline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
AU2019317810A1 (en) 2018-08-09 2021-02-25 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in HIV therapy
US11572595B2 (en) * 2018-12-31 2023-02-07 Roche Molecular Systems, Inc. Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
CN113811360A (zh) 2019-03-06 2021-12-17 葛兰素史密斯克莱知识产权（第2 号）有限公司 用于hiv治疗的化合物
CA3146679A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
KR20220066303A (ko) 2019-09-11 2022-05-24 더 스크립스 리서치 인스티튜트 항바이러스 전구약물 및 이의 약제학적 조성물
CN121358747A (zh) 2023-06-27 2026-01-16 吉利德科学公司 核苷逆转录酶易位抑制剂的固体形式
CN121419986A (zh) 2023-06-27 2026-01-27 吉利德科学公司 用于制备抗病毒前药的方法和中间体

Also Published As

Publication number Publication date
AU2020346908A1 (en) 2022-03-24
EP4028020A1 (en) 2022-07-20
CN114793421B (zh) 2024-09-13
CL2024003241A1 (es) 2025-01-03
JP2022547558A (ja) 2022-11-14
EP4028019A1 (en) 2022-07-20
IL320979B1 (en) 2026-04-01
EP4028020A4 (en) 2023-09-27
CL2022000601A1 (es) 2022-10-28
CN119462802A (zh) 2025-02-18
AU2020346907A2 (en) 2022-06-16
DOP2022000055A (es) 2022-06-15
AU2020346907A1 (en) 2022-03-24
JP2025096427A (ja) 2025-06-26
CN114793421A (zh) 2022-07-26
AU2020346908A2 (en) 2022-06-16
US20220332751A1 (en) 2022-10-20
BR112022004417A2 (pt) 2022-06-21
US20230390318A1 (en) 2023-12-07
MX2022002899A (es) 2022-05-16
CL2022000587A1 (es) 2022-10-28
DOP2022000056A (es) 2022-06-15
CO2022005128A2 (es) 2022-05-10
IL290919B2 (en) 2025-10-01
CR20220110A (es) 2022-06-16
PE20221037A1 (es) 2022-06-17
CR20220109A (es) 2022-06-07
MX2025014404A (es) 2026-01-07
CA3150418A1 (en) 2021-03-18
CN114929236B (zh) 2024-06-07
KR20220066303A (ko) 2022-05-24
IL319709A (en) 2025-05-01
EP4028019A4 (en) 2024-04-17
IL320979A (en) 2025-07-01
JP7703518B2 (ja) 2025-07-07
IL290919A (en) 2022-04-01
PH12022550528A1 (en) 2023-09-04
IL290861A (en) 2022-04-01
US12569510B2 (en) 2026-03-10
BR112022004424A2 (pt) 2022-05-31
UA130229C2 (uk) 2025-12-24
JP7719769B2 (ja) 2025-08-06
WO2021050961A1 (en) 2021-03-18
IL290861B1 (en) 2025-04-01
JP2025137788A (ja) 2025-09-19
CN114929236A (zh) 2022-08-19
AU2020346908B2 (en) 2026-02-12
JP2022547978A (ja) 2022-11-16
CA3150467A1 (en) 2021-03-18
MX2022002897A (es) 2022-05-16
CL2025003801A1 (es) 2026-03-27
WO2021050956A1 (en) 2021-03-18
IL290919B1 (en) 2025-06-01
MX2025011432A (es) 2025-11-03
CO2022004681A2 (es) 2022-07-19
US20220323476A1 (en) 2022-10-13
KR20220066302A (ko) 2022-05-24
NZ786022A (en) 2025-05-30
IL290861B2 (en) 2025-08-01
PH12022550527A1 (en) 2023-09-04
CN118580291A (zh) 2024-09-03
NZ786018A (en) 2025-05-30

Similar Documents

Publication Publication Date Title
PE20221036A1 (es) Profarmacos antivirales y formulaciones de los mismos
PE20170197A1 (es) Derivados de nucleosido 4'-sustitutos como inhibidores de la transcriptasa reversa de vih
PE20230618A1 (es) Analogos de nucleosido de 1'-ciano y usos de los mismos
PE20020216A1 (es) PRODROGAS 3' DE 2' -DESOXI-ß-L-NUCLEOSIDOS
PE20120013A1 (es) Fosforamidato derivados de guanosina compuestos nucleosidos para tratamiento de infecciones virales
PE20091424A1 (es) Nucleosidos 2',4'-sustituidos como agentes antivirales
CO6382185A2 (es) Compuestos nucleosidos antivirales
CO6331439A2 (es) 1-2 bicíclicos pirimidinona carboxamida como inhibidores de la integrasa del virus de inmunodeficiencia humana
MX2021001056A (es) Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas.
CL2010000520A1 (es) Forma cristalina del propanoato de (s) - isopropil 2 -(((s) - (((2r,3r,4r,5r) - 5- (2,4-dioxo-3,4-dihidropirimidim-1(2h) -il)-4-fluoro-3-hidroxi-4-metitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino); proceso de preparacion; composicion framaceutica; y su uso para el tratamiento de una infeccion causada por el virus de la hepatitis c.
TW200600503A (en) Bicyclic heterocycles as hiv integrase inhibitors
ES2139567T3 (es) Secuencias nucleotidicas procedentes del genoma de retrovirus del tipo vih-1 y sus aplicaciones para la amplificacion de los genomas de estos retrovirus y para el diagnostico in vitro de las infecciones producidas por estos virus.
MA46038A (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
WO2006012078A3 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
TW200738728A (en) HIV integrase inhibitors
SV2009003294A (es) Inhibidores de transcriptasa inversa no nucleosidicos
DOP2023000026A (es) Profármacos de análogos de nucleótidos de fosfonamida y su uso farmaceutico
MX2022010926A (es) Compuestos para su uso en infecciones viricas.
CO2020008887A2 (es) Inhibidores de pi4kiiiβ
EA200701406A1 (ru) Приемлемые для лечения вич соединения
EA201800388A1 (ru) Макрогетероциклические нуклеозидные производные и их аналоги, получение и применение
JOP20220033A1 (ar) نظام توصيل أدوية لتوصيل العوامل المضادة للفيروسات
WO2008154246A8 (en) Hiv integrase inhibitors
MX2021006992A (es) Análogos de nucleósidos de ciclobutilo como antivirales.
CO2025010224A2 (es) Profármacos de inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4'